ClinicalTrials.gg
CompletedNCT03070990Updated Oct 18, 2024

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

A Phase 1 interventional study of Enfortumab vedotin in Metastatic Urothelial Cancer, sponsored by Astellas Pharma Inc. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Astellas Pharma Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell — 10 open to participants now, 15 under way, 1 of them phase 3. enfortumab vedotin · Carcinoma, Transitional Cell.

Enrollment
18th of 20
19 · median 49
Started
2017
with 2 others
Phase 1
4 of 20
1 open now
Registered
1st of 20
by date
Lead sponsor
2 of 20
Astellas Pharma Inc

Among the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, this one is the 18th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 1, and was the 1st registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

10 of the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About enfortumab vedotin

enfortumab vedotin: first FDA approval 2019 (PADCEV), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety, tolerability and pharmacokinetics of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma. This study will also assess the immunogenicity as defined by the incidence of anti-drug antibody (ADA) and anti-tumor activity of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma.

Read the detailed description

All subjects will receive a single 30 minute intravenous (IV) infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.

03

Conditions studied

  • Metastatic Urothelial Cancer

Keywords

  • Urothelial Carcinoma
  • Enfortumab vedotin
  • ASG-22CE
  • Padcev
  • ASG-22ME
  • Metastatic Urothelial Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have confirmed, locally advanced (TNM classification T3b and any N; or T and N2-3) or Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e., cancer of the bladder, renal pelvis, ureter, or urethra). Subjects with Urothelial Carcinoma with squamous differentiation or mixed cell types are eligible.
  • Subject must be able to submit a tumor tissue samples for Nectin-4 expression analysis at central laboratory.
  • Subject must have failed at least one prior chemotherapy regimen for advanced disease. Urothelial and bladder cancer subjects are not required to have failed prior chemotherapy regimen if considered unfit for cisplatin-based chemotherapy.
  • Subject must have according to Response Evaluation Criteria in Solid Tumor () (version 1.1).
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Preexisting sensory neuropathy Grade ≥ 2.
  • Preexisting motor neuropathy Grade ≥ 2.
  • Uncontrolled central nervous system that requires active treatment.
  • Any anticancer therapy within 14 days prior to the first dose of study drug.
  • Subjects with pre-existing immunotherapy-related adverse events requiring high doses of systemic are not eligible.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Arm A: Enfortumab vedotin 1.0 mg/kg

    All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.

    Drug: Enfortumab vedotin

  • Experimental
    Arm B: Enfortumab vedotin 1.25 mg/kg

    All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.

    Drug: Enfortumab vedotin

Interventions

  • All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.

    Also known as: ASG-22CE, Padcev

06

What researchers measure

Primary outcomes

  1. Safety assessed by incidence of adverse events

    Adverse events will be coded using MedDRA. Adverse events collection begins after signing informed consent and collected until 28 days after the last dose of study drug.

    Time frame: Up to 12 months

  2. Safety assessed by laboratory tests: Hematology

    Descriptive statistics will be used to summarize results.

    Time frame: Up to 12 months

  3. Safety assessed by laboratory tests: Biochemistry

    Descriptive statistics will be used to summarize results.

    Time frame: Up to 12 months

  4. Safety assessed by laboratory tests: Urinalysis

    Descriptive statistics will be used to summarize results.

    Time frame: Up to 12 months

  5. Safety assessed by laboratory tests: Coagulation studies

    Descriptive statistics will be used to summarize results.

    Time frame: Up to 12 months

  6. Number of participants with vital sign abnormalities and/or adverse events

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 12 months

  7. Safety assessed by electrocardiogram (ECG)

    Before measurement of ECGs, the participant should be resting in a supine position for at least 5 minutes. The investigator will assess the ECG charts as "normal", "abnormal (not clinically significant)" or "abnormal (clinically significant)". "Abnormal (not clinically significant)" and "abnormal (clinically significant)" findings will be recorded.

    Time frame: Up to 12 months

  8. Pharmacokinetics (PK) parameter for total antibody (TAb): Concentration at the end of infusion (CEOI)

    CEOI will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  9. Pharmacokinetics (PK) parameter for antibody drug conjugate (ADC): CEOI

    CEOI will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  10. Pharmacokinetics (PK) parameter for Monomethyl Auristatin E (MMAE): CEOI

    CEOI will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  11. PK parameter for TAb: Maximum observed concentration (Cmax)

    Cmax will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  12. PK parameter for ADC: Cmax

    Cmax will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  13. PK parameter for MMAE: Cmax

    Cmax will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  14. PK parameter for TAb: Trough concentration (Ctrough)

    Ctrough will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  15. PK parameter for ADC: Ctrough

    Ctrough will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  16. PK parameter for MMAE: Ctrough

    Ctrough will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  17. PK parameter for TAb: Time to maximum concentration (Tmax)

    Tmax will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  18. PK parameter for ADC: Tmax

    Tmax will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  19. PK parameter for MMAE: Tmax

    Tmax will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  20. PK parameter for TAb: Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-7)

    AUC0-7 will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  21. PK parameter for ADC: AUC0-7

    AUC0-7 will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  22. PK parameter for MMAE: AUC0-7

    AUC0-7 will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  23. PK parameter for TAb: Terminal or apparent terminal half-life (t1/2)

    T1/2 will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  24. PK parameter for ADC: t1/2

    T1/2 will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

  25. PK parameter for MMAE: t1/2

    T1/2 will be derived from the PK blood samples collected.

    Time frame: Days 1-4, 8, 15-18, 22 of Cycle 1, Day 1 of Cycle 2 and 3, and subsequent cycles up to an average of 12 months

Secondary outcomes

  1. Incidence of Anti-Drug Antibody (ADA)

    Blood samples for anti-drug antibody (ADA) analysis will be collected.

    Time frame: Up to 12 months

  2. Overall Response Rate

    Defined as the proportion of subjects whose best overall response is rated as complete response (CR) or partial response (PR)

    Time frame: Up to 12 months

  3. Disease Control Rate

    Defined as the proportion of subjects whose best overall response is rated as CR, PR, or stable disease (SD)

    Time frame: Up to 12 months

07

Study locations

8 sites
  • Site JP00003
    Tsukuba, Ibaraki, Japan
  • Site JP00005
    Sendai, Miyagi, Japan
  • Site JP00008
    Suita, Osaka, Japan
  • Site JP00004
    Chuo-ku, Tokyo, Japan
  • Site JP00007
    Koto-ku, Tokyo, Japan
  • Site JP00006
    Fukuoka, Japan
  • Site JP00001
    Niigata, Japan
  • Site JP00002
    Okayama, Japan
08

References and documents

Publications

  • Takahashi S, Uemura M, Kimura T, Kawasaki Y, Takamoto A, Yamaguchi A, Melhem-Bertrandt A, Gartner EM, Inoue T, Akazawa R, Kadokura T, Tanikawa T. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. Invest New Drugs. 2020 Aug;38(4):1056-1066. doi: 10.1007/s10637-019-00844-x. Epub 2019 Aug 14. PubMed 31444589 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Feb 2019, 22 months.

Of 62 industry-sponsored phase 1 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's 22 months is below that.

Counting every sponsor, half of 99 studies reached it within 44 months; a quarter within 31 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2017
First posted
Mar 6, 2017
StartActual
Apr 24, 2017
Primary completionActual
Feb 25, 2019
CompletionActual
Feb 25, 2019
Last update
Oct 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03070990
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Mar 6, 2017
Start date
Apr 24, 2017
Primary completion
Feb 25, 2019
Completion
Feb 25, 2019
Last update
Oct 18, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enfortumab vedotin

Start the discussion